Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

Atellica® CH Diazo Direct Bilirubin (D_DBil)

K-Number: K223078 · 2023-06-12

Decision Date2023-06-12
Product CodeCIG
Advisory CommitteeCH
DecisionSubstantially Equivalent

Device Summary

Atellica® CH Diazo Direct Bilirubin (D_DBil) is a medical device manufactured by Siemens Healthcare Diagnostics, Inc.. It received FDA 510(k) clearance on 2023-06-12 under approval number K223078. The device is classified under product code CIG. It was reviewed by the CH advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Atellica® CH Diazo Direct Bilirubin (D_DBil)?

Atellica® CH Diazo Direct Bilirubin (D_DBil) is a medical device that received FDA 510(k) clearance on 2023-06-12. It is manufactured by Siemens Healthcare Diagnostics, Inc.. The 510(k) number is K223078.

When was Atellica® CH Diazo Direct Bilirubin (D_DBil) approved by the FDA?

Atellica® CH Diazo Direct Bilirubin (D_DBil) received FDA 510(k) clearance on 2023-06-12, under approval number K223078.

What company makes Atellica® CH Diazo Direct Bilirubin (D_DBil)?

Atellica® CH Diazo Direct Bilirubin (D_DBil) is manufactured by Siemens Healthcare Diagnostics, Inc..

What is the FDA product code for Atellica® CH Diazo Direct Bilirubin (D_DBil)?

The FDA product code for Atellica® CH Diazo Direct Bilirubin (D_DBil) is CIG.

Other Devices by Siemens Healthcare Diagnostics, Inc.

View all 71 devices →

Related Devices (Code: CIG)

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.